5.61
-2.26%
Close of 9 Nov 2026, in CNY
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Guangdong Hybribio Biotech Co
Its shares trade on Shenzhen under the ticker 300639.SZ. It has been listed since 12 April 2017. In the fiscal year to 31 December 2025, it reported a net loss of CN¥130.9m. At that date it held total assets of CN¥4.15bn and shareholders' equity of CN¥3.75bn.
Guangdong Hybribio Biotech Co., Ltd. engages in the research, development, production, and sale of nucleic acid molecular diagnostic products in China. The company is headquartered in Chaozhou, Guangdong. The company went IPO on 2017-04-12. The firm operates two segments. The In Vitro Diagnostic Reagents and Supporting Equipment segment operates the research, development and production of nucleic acid detection reagents and supporting equipment, such as cervical cancer detection series products, deafness susceptibility gene detection series products and reproductive health management series products. The products are used in hospital clinical testing, large-scale population screening and other areas. The Medical Testing Service segment is involved in providing medical testing services for medical institutions, and the testing programs cover genetic metabolic diseases, infectious diseases, molecular pathological testing and tumor examinations.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 12 Apr 2017
- Employees
- 3,339
- Website
- hybribio.cn ↗
Leadership
Pay as last reported
- Mr. Qiaozhong GuanChairman of the Board, since 2022CN¥2.7m
- Mr. Weixiong HuangVice Chairman of the Board, since 2022CN¥300,000
- Mr. Qinghui LiChief Financial OfficerCN¥729,600
- Ms. Jianyu WangGeneral Manager, Director, since 2022CN¥2.6m
- Mr. Yi ChenDeputy General Manager, Secretary of the Board, since 2017CN¥870,800
- Mr. Zhisheng GuanExecutive Deputy General Manager, Director, since 2022CN¥3.1m
- Ms. Danrong WengDeputy General ManagerCN¥877,400
- Mr. Xiaochuan LiChief Medical Officer
- Mr. Longxu XieStaff Elected DirectorCN¥1.1m
- Ms. Xiaoyan YangDirectorCN¥120,000
- Mr. Yingshi ChenIndependent Director
- Mr. Youlin QiaoIndependent Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Guangdong Hybribio Biotech employs 3,339 full-time employees in Chaozhou, China.
- The company develops nucleic acid molecular diagnostic products for hospital clinical testing and population screening.
- Guangdong Hybribio Biotech operates two segments: In Vitro Diagnostic Reagents and Medical Testing Services.
Weaknesses
- The company's products are limited to nucleic acid molecular diagnostics in China.
- Guangdong Hybribio Biotech has no international presence beyond China.
- The firm's IPO was in 2017, indicating limited market experience.
Opportunities
- The In Vitro Diagnostic Reagents segment can expand into cervical cancer detection series products.
- Medical Testing Services can grow in genetic metabolic disease testing programs.
- China's healthcare market offers growth for nucleic acid molecular diagnostics.
Threats
- The company faces competition from other Chinese biotech firms in nucleic acid diagnostics.
- Guangdong Hybribio Biotech's reliance on China's healthcare market poses a risk.
- Regulatory changes in China could impact the medical testing service segment.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.